Aldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., is a biotechnology company. The Company is focused primarily on the development of new products for immune-mediated, inflammatory, orphan and other diseases that are caused by naturally occurring toxic chemical species known as free aldehydes. The Company has developed a series of product candidates that are designed specifically to trap and allow for the degradation of free aldehydes. The Company's most advanced product candidate is an eye drop formulation of NS2, which is under development for the treatment of Sjogren-Larsson Syndrome (SLS). The Company has completed a double-masked, placebo-controlled, Phase I clinical testing of 0.25% and 0.5% NS2 administered as an eye drop for safety and tolerability in approximately 48 healthy volunteers. Data from the Phase I study demonstrated that NS2 was well tolerated in all subjects throughout the duration of the study.
Company Growth (employees)